Genelux (GNLX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jun, 2026Opening remarks and agenda
Meeting called to order by the President, CEO, and Chairman, with board members, executive team, and external advisors present.
Agenda included two proposals: election of a Class I director and ratification of the independent auditor.
Board and executive committee updates
Board members and key executives, including the CFO, CMO, and General Counsel, were introduced at the start of the meeting.
Shareholder proposals
Two proposals presented: election of John Smither as Class I director and ratification of Weinberg & Company, P.A. as independent auditor for 2026.
No additional proposals were submitted by stockholders in accordance with bylaws.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Genelux
- Olvi-Vec shows robust efficacy in hard-to-treat cancers, with pivotal data expected this year.GNLX
Fireside chat7 Jun 2026 - Directors were elected, auditor ratified, and a business update is planned for the fall.GNLX
AGM 20256 Jun 2026 - Olvi-Vec shows promising late-stage efficacy and immune activation in ovarian and lung cancers.GNLX
Corporate presentation1 Jun 2026 - Net loss narrowed, R&D spending rose, $30M raised, and cash runway extends into Q1 2026.GNLX
Q2 20241 Jun 2026 - Net loss of $20.9M for nine months; cash runway into Q1 2026; key trial data ahead.GNLX
Q3 20241 Jun 2026 - FDA alignment and clinical progress drive R&D, with cash runway into Q1 2026.GNLX
Q4 20241 Jun 2026 - Net loss narrowed to $7.5M in Q1 2025; cash runway to Q3 2026 after equity raises.GNLX
Q1 20251 Jun 2026 - Cash reserves fund operations into Q3 2026 as clinical progress continues amid ongoing losses.GNLX
Q2 20251 Jun 2026 - Net loss reached $22.9M YTD; cash runway extends into Q3 2026, with key data ahead.GNLX
Q3 20251 Jun 2026